Dima Biotechnology

DIMA Biotechnology Ltd. is a leading biotech firm specializing in preclinical R&D solutions for the Biopharma industry. We offer pre-designed validated antibody molecules tailored to BioPharma research. Our goal is to develop antibodies for all potential drug targets, accelerating drug discovery for BioPharma. We excel in innovative antibody tech: 1. DiMPro™ Membrane Protein Platform: Express and purify membrane proteins, including GPCRs and ion channels, using mammalian cells. Our inventory includes functional proteins with five distinct solutions. DimAb® Single B Cell Antibody Discovery Platform: Access over positive hits in one month through our DimAb® B cell library. DiLibrary™ Mammalian Display Antibody Engineering Platform: Superior antibody engineering for humanization, affinity maturation, and more, outperforming phage or yeast displays. DiAssay™ Antibody Evaluation Platform: Screening processes for Bispecific Antibodies, Antibody-Drug Conjugates, and CAR-T Therapies. Our mission is to empower the BioPharma sector with advanced solutions, fostering innovation and expediting life-changing therapy development.